The bill prohibits these agreements between brand name and generic drug manufacturers by making them presumptively anticompetitive if the nonreference drug maker receives anything of value from the other company. The bill would make violating these provisions punishable by civil penalty.
Earlier this week, California Governor Gavin Newsom signed into law AB 824, which makes the state the first to bar pay-for-delay pharmaceutical agreements.
The bill prohibits these agreements between brand name and generic drug manufacturers by making them presumptively anticompetitive if the nonreference drug maker receives anything of value from the other company. The bill would make violating these provisions punishable by civil penalty.
Citing a Federal Trade Commission report that says that anticompetitive deals cost consumers and taxpayers $3.5 billion in higher drug costs every year, the state says that blocking the development of generic drug competition harms consumers and increases drug company profits.
Increased competition from generics and biosimilars breaks up drug monopolies and lowers pharmaceutical costs, the state says. California patients and state programs saved $26 billion in 2018 alone by using generic prescription drugs.
However, the Association of Accessible Medicines (AAM), which represents generic and biosimilar drug makers, claims the law will actually have the opposite effect.
“AB 824 will harm patients in California by denying them earlier access to affordable generic and biosimilar prescriptions drugs. Moreover, by attempting to regulate federal patents and transactions that occur wholly in other states, the law violates the US Constitution," according to a statement from Chip Davis, president and chief executive officer of AAM.
Earlier this year, the Biosimilars Council, a part of AAM, released a white paper that, while condemning abuses of the patent system that delay biosimilar competition, also warned against legislative overreach into regulating pay-for-delay deals, which the council characterizes as “pro-competitive.”
According to the council, the settlements related to brand-name adalimumab, for example, “provide for competition 11 years earlier than might otherwise be possible…if the manufacturers of biosimilars to Humira were not able to settle, competition could have been delayed until 2034.”
Legislative proposals to regulate agreements that end patent litigation, like the one enacted in California, could backfire, AAM fears. A ban on the agreements could create “a de facto prohibition on patent settlements,” which would “merely benefit companies investing in the creation of patent thickets” by “forcing competitors to slog through lengthy and expensive litigation with uncertain prospects of success.”
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.